Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2017 (2017), Article ID 9583257, 4 pages
https://doi.org/10.1155/2017/9583257
Case Report

Ibrutinib Treatment of Mantle Cell Lymphoma Relapsing at Central Nervous System: A Case Report and Literature Review

Hematology Unit, Papardo Hospital, c/da Papardo, 98158 Messina, Italy

Correspondence should be addressed to Donato Mannina

Received 15 December 2016; Accepted 12 June 2017; Published 16 July 2017

Academic Editor: Sudhir Tauro

Copyright © 2017 Donato Mannina and Barbara Loteta. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Mantle cell lymphoma (MCL) accounts for about 5% of all lymphomas. Its clinical and histological features are heterogeneous. After a frequently good initial response, the disease generally and repeatedly relapses and finally the outcome is poor. Particularly severe is the prognosis of the rare occurrence of CNSi (Central Nervous System involvement). Ibrutinib, an oral inhibitor of Bruton tyrosine kinase (BTK), has shown strong activity in relapsing patients with Chronic Lymphocytic Leukemia (CLL) and MCL. Few reports are available about treatment with ibrutinib of patients presenting CNSi by lymphoproliferative diseases (LPD). In all of them, ibrutinib, at the dosage between 420 and 560 mg/day, showed an impressive effectiveness. Here we describe a case of MCL with CNS relapse showing an excellent response to ibrutinib administered at the unusual dose of 280 mg/day because of concomitant treatment of cardiological disease.